Unicycive Therapeutics Inc

UNCY12 Jan 2025
Healthcare
$0.74
-0.11 (-10.81%)
Lowest Today
$0.65
Highest Today
$0.74
Today’s Open
$0.74
Prev. Close
$0.74
52 Week High
$1.82
52 Week Low
$0.2
To Invest in Unicycive Therapeutics Inc

Unicycive Therapeutics Inc

Healthcare
UNCY12 Jan 2025
-0.11 (-10.81%)
1M
3M
6M
1Y
5Y
Low
$0.64
Day’s Range
High
$0.74
0.64
52 Week Low
$0.2
52-Week Range
52 Week High
$1.82
0.2
1 Day
-
1 Week
-12.02%
1 month return
-10.49%
3 month return
+67.96%
6 month return
+34.57%
1 Year return
-21.41%
3 Years return
-63.53%
5 Years return
-
10 Years return
-
Institutional Holdings
Great Point Partners LLC
8.25
Octagon Capital Advisors LP
8.25
Logos Global Management LP
4.89
Walleye Trading Advisors, LLC
4.82
Vivo Capital, LLC
4.31
SILVERARC CAPITAL MANAGEMENT, LLC
3.85
Nantahala Capital Management, LLC
2.72

Market Status

Fundamentals
Market Cap
68.96 mln
PB Ratio
2.48
PE Ratio
0
Enterprise Value
37.42 mln
Total Assets
14.19 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Organisation
Unicycive Therapeutics Inc
Employees
14
Industry
Biotechnology
CEO
Dr. Shalabh K. Gupta M.D., MPA
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities